Shopping Cart
Remove All
Your shopping cart is currently empty
Glutaminase-IN-1 (CB839 derivative), a novel 1,3,4-selenodiazepine inhibitor of the renal-type glutaminase (KGA) variant, exhibited antitumor activity in an aggressive H22 hepatocellular carcinoma xenograft model.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | - | In Stock |
| Description | Glutaminase-IN-1 (CB839 derivative), a novel 1,3,4-selenodiazepine inhibitor of the renal-type glutaminase (KGA) variant, exhibited antitumor activity in an aggressive H22 hepatocellular carcinoma xenograft model. |
| Targets&IC50 | A549 cells:17 nM, H2:6.78 μM, Caki-1 cells:19 nM, HCT116 cells:9 nM, KGA:1 nM |
| In vitro | Glutaminase-IN-1 (CPD20) is a derivative of CB839, serving as a conformational inhibitor of kidney-type glutaminase (KGA) with an IC50 of 1 nM. Glutaminase-IN-1 exhibits improved cellular uptake and anti-tumor activity. The IC50 values of Glutaminase-IN-1 in A549, H2, Caki-1, and HCT116 cell lines are 17 nM, 6.78 μM, 19 nM, and 9 nM, respectively. Glutaminase-IN-1 demonstrates superior KGA inhibitory activity compared to the corresponding BPTES and CB839[1]. |
| In vivo | Glutaminase-IN-1 (10 mg/kg, subcutaneous) reduced the size and weight of HCT116 tumors, and statistical analysis indicated a significant 40% reduction in tumor weight with CPD20. Glutaminase-IN-1 significantly prolonged the survival of mice carrying H22[1]. |
| Synonyms | CB839 derivative |
| Molecular Weight | 618.47 |
| Formula | C26H24F3N7O3Se |
| Cas No. | 2247127-79-1 |
| Smiles | C(C(NC1=CC=C(CCCCC=2[Se]C(NC(CC3=CC=CC=N3)=O)=NN2)N=N1)=O)C4=CC(OC(F)(F)F)=CC=C4 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (161.69 mM), Sonication is recommended. H2O: 1 mg/mL (1.61 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.